Vallon Pharmaceuticals Announces Presentation of ADAIR Pharmacokinetics and Pharmacodynamic Data at the Virtual 2021 APSARD Annual Meeting ADAIR demonstrated bioequivalence to immediate release (IR) d-AMPH when administered orally and appears to be less desirable to recreational drug abusers when snorted compared to currently available...

Data from Vallon Pharmaceuticals’ ADAIR Selected for Symposia Presentation at the Virtual 2021 APSARD Annual Meeting PHILADELPHIA, PA, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc., (“Vallon” or the “Company”), a biopharmaceutical company focused on the development of novel drugs for CNS disorders,...